Literature DB >> 19366851

Pretreatment insulin-like growth factor-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease.

N R Biermasz1, M J E Wassenaar, A A van der Klaauw, A M Pereira, J W A Smit, F Roelfsema, R Wolterbeek, H M Kroon, M Kloppenburg, J A Romijn.   

Abstract

OBJECTIVE: The aim of the study was to identify factors influencing the development of osteoarthritis during long-term control of acromegaly, focusing on disease-specific parameters, GH and IGF-I concentrations, and duration of disease, adjusted for the well-known determinants of primary osteoarthritis.
DESIGN: We conducted a follow-up study.
METHODS: We studied 67 patients with adequate biochemical control of acromegaly for a mean of almost 13 yr. Study parameters were the results of radiological assessment of the spine, hip, knee, and hand. Osteoarthritis was defined as radiological osteoarthritis using the scoring system developed by Kellgren and Lawrence. Correlations between potential factors of influence and osteoarthritis were performed by analysis of covariance and adjusted for age, gender, and body mass index.
RESULTS: Patients with pretreatment IGF-I sd scores in the highest tertile had an almost 4-fold increased risk for radiological osteoarthritis of the hip when compared with patients in the lowest tertile. After adjustment for age, gender, BMI, and disease duration, pretreatment IGF-I sd scores predicted radiographic osteoarthritis in all joint sites. Osteoarthritis was not predicted by other factors, including pretreatment GH levels, type of treatment, and duration of follow-up.
CONCLUSION: This is the first study to document pretreatment IGF-I concentration as a predictor of radiographic osteoarthritis in acromegalic patients with long-term disease control.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19366851     DOI: 10.1210/jc.2008-2393

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

1.  Clinical and functional outcome of total hip arthroplasty in patients with acromegaly: mean twelve year follow-up.

Authors:  Mustafa Akkaya; Antonio Pignataro; Nemandra Sandiford; Thorsten Gehrke; Mustafa Citak
Journal:  Int Orthop       Date:  2022-05-21       Impact factor: 3.479

Review 2.  Acromegaly in the elderly patients.

Authors:  Maria Rosaria Ambrosio; Irene Gagliardi; Sabrina Chiloiro; Ana Gonçalves Ferreira; Marta Bondanelli; Antonella Giampietro; Antonio Bianchi; Laura De Marinis; Maria Fleseriu; Maria Chiara Zatelli
Journal:  Endocrine       Date:  2020-02-14       Impact factor: 3.633

3.  Functional evaluation of the joints in acromegalic patients and associated factors.

Authors:  Leandro Lemgruber Kropf; Miguel Madeira; Leonardo Vieira Neto; Mônica Roberto Gadelha; Maria Lucia Fleiuss de Farias
Journal:  Clin Rheumatol       Date:  2013-03-13       Impact factor: 2.980

4.  Analysis of osteoarthritis in a mouse model of the progeroid human DNA repair syndrome trichothiodystrophy.

Authors:  Sander M Botter; Michel Zar; Gerjo J V M van Osch; Harry van Steeg; Martijn E T Dollé; Jan H J Hoeijmakers; Harrie Weinans; Johannes P T M van Leeuwen
Journal:  Age (Dordr)       Date:  2010-09-07

5.  Clinical manifestations and diagnosis of acromegaly.

Authors:  Gloria Lugo; Lara Pena; Fernando Cordido
Journal:  Int J Endocrinol       Date:  2012-02-01       Impact factor: 3.257

6.  The Effect of Aging on Quality of Life in Acromegaly Patients Under Treatment.

Authors:  Naoki Yamamoto; Shin Urai; Hidenori Fukuoka; Masaaki Yamamoto; Kenichi Yoshida; Masaki Suzuki; Hiroki Shichi; Yasunori Fujita; Keitaro Kanie; Genzo Iguchi; Yutaka Takahashi; Wataru Ogawa
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-03       Impact factor: 5.555

7.  Clinical and radiographic assessment of peripheral joints in controlled acromegaly.

Authors:  Iris C M Pelsma; Herman M Kroon; Victoria R van Trigt; Alberto M Pereira; Margreet Kloppenburg; Nienke R Biermasz; Kim M J A Claessen
Journal:  Pituitary       Date:  2022-06-20       Impact factor: 3.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.